Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
Medicines shouldn’t be a luxury Take action
Get involved
Our campaigns

Latest Feature Stories

Latest Feature Stories

Feature story |
22 February 2012
HIV/AIDS Intellectual property and trade Tuberculosis
Myanmar

Lives in the Balance: the story of Maung Myint, a TB and HIV patient struggling to get lifesaving treatment in Myanmar, as donors slash future funding

5 min
Feature story |
13 February 2012
Intellectual property and trade
India

Timeline of Key Events in Novartis's attack on the pharmacy of the developing world

3 min
As India and the European Union prepare to meet at a New Delhi summit to finalize a Free Trade Agreement (FTA) under negotiation since 2007, Médecins Sans Frontières / Doctors Without Borders (MSF), the Treatment Action Campaign (TAC), SECTION27 and He-Tic held a picket to warn that harmful provisions in the agreement could have a severely negative impact on access to medicine for people in developing countries. Photograph by Borrie Lagrange
Feature story
Feature story |
10 February 2012
HIV/AIDS Intellectual property and trade
South AfricaEuropean Union

Photos from Global Actions Ahead Of EU-India FTA Summit

MSF staff conduct a home-based visit for a DR-TB patient in Kampong Cham province, Cambodia. Photograph by Eddy McCall
Feature story
Feature story |
21 December 2011
HIV/AIDS Intellectual property and trade Tuberculosis
Cambodia

MSF steps up TB support in Cambodia

7 min
Novartis has been pursuing a legal case aimed at gutting India’s patent law of important public health safeguards since 2006. The law allows companies in India to produce affordable generic medicines on which MSF and other care providers in developing countries heavily rely to do our work.  A protest was organised by Indian civil society on World AIDS Day, 1 December 2011, in front of Novartis' Mumbai Office. Photograph by Claudio Tommasini
Feature story
Feature story |
07 December 2011
HIV/AIDS Intellectual property and trade
India

Photos from World AIDS Day Action at Novartis offices in Mumbai

Feature story |
01 December 2011
HIV/AIDS Intellectual property and trade Malaria Tuberculosis

The thinnest of lifelines: An interview with MSF President, Dr Unni Karunakara on MSF’s response to the funding crisis at the Global Fund

7 min
Feature story |
29 November 2011
HIV/AIDS Intellectual property and trade
India

Novartis case: New date and the government's defence

Feature story |
24 November 2011
HIV/AIDS Tuberculosis
Myanmar

Myanmar: HIV/AIDS is still a taboo subject

4 min
  • Load More
Navigate
  • About MSF Access
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access
Médecins Sans Frontières
140 Route de Ferney
1202 Geneva, Switzerland
Phone:+41 22 849 8484
E-mail: [email protected]

Follow us

  • X
  • Facebook
  • YouTube
  • Medium
Medicines Shouldn't Be A Luxury